HomeInvestor Relations

Investor Relations

Investor Home

Corporate Profile

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate... More

Stock Quote

MNOV (Common)
ExchangeNASDAQ (US Dollar)
Price$2.00
Change (%)0.00 (0.00%)
Volume14,053
Data as of 07/10/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

2012 Annual Report

Recent News

More
DateTitle 
07/07/14MediciNova to Present Data on MN-001 for the Treatment of NASH (Nonalcoholic Steatohepatitis) During the JDDW 2014 (Japan Digestive Disease Week 2014)Printer Friendly Version
06/11/14MediciNova Announces Positive Results in Study of MN-001 in Mouse Model of Pulmonary FibrosisPrinter Friendly Version
04/08/14MediciNova Appoints Yoshio Ishizaka to its Board of DirectorsPrinter Friendly Version
04/08/14MediciNova Announces Management AppointmentPrinter Friendly Version

Upcoming Events

More
There are currently no events scheduled.

What's New

There are currently no items available.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Medicinova Inc posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Recent News